Ramucirumab therapy in patients with advanced gastric cancer: discussion of a case series

Cover Page

Cite item

Full Text

Abstract

Background. Gastric cancer is the fifth most common malignancy worldwide with diagnosis often occurring at an advanced stage. For the majority of advanced gastric cancer patients, chemotherapy typically is used as first-line treatment, although many patients will also require second-line treatment. Ramucirumab (Cyramza®, Eli Lilly and Company, Indianapolis, Indiana, USA) recently has received worldwide and United States Food and Drug Administration approval for gastric cancer in the second-line setting. Case reports. A series of five advanced gastric cancer cases is presented, outlining each patient’s diagnosis and treatment. All patients were treated with intravenous ramucirumab (8 mg/kg on days 1 and 15) plus paclitaxel (80 or 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle) after disease progression on or after first-line chemotherapy. Patient outcomes are described including an outline of treatment-related adverse events and quality of life. All patients were able to achieve a clinical response and stable disease. Conclusion. Our case series demonstrates that ramucirumab, in conjunction with paclitaxel, is an effective and well-tolerated treatment option for advanced gastric cancer patients who have disease progression following first-line chemotherapy.

About the authors

R V Orlova

Saint Petersburg State University

д-р мед. наук, проф., зав. каф. онкологии 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9

L G Zhukova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Email: zhukova.lyudmila@rambler.ru
д-р мед. наук, и.о. зав. отд-нием химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

I P Ganshina

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, вед. науч. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

D Yu Yukalchuk

Irkutsk Regional Oncological Dispensary

канд. мед. наук, врач высшей категории 664035, Russian Federation, Irkutsk, ul. Frunze, d. 32

D M Ponomarenko

Irkutsk Regional Oncological Dispensary

канд. мед. наук, зав. химиотерапевтическим отд-нием; врач высшей категории 664035, Russian Federation, Irkutsk, ul. Frunze, d. 32

N P Beliak

City Clinical Oncology Dispensary

канд. мед. наук, врач-онколог 11-го химиотерапевтического отд-ния 198255, Russian Federation, Saint Petersburg, Prospect Veteranov, d. 56

O O Gordeeva

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

аспирант отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

S P Erdniev

City Clinical Oncology Dispensary

канд. мед. наук, зав. химиотерапевтическим отд-нием 198255, Russian Federation, Saint Petersburg, Prospect Veteranov, d. 56

A A Minasyan

Eli Lilly and Company

науч. советник по клин. исследованиям 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10

A A Dashkova

Eli Lilly and Company

канд. мед. наук, мед. конс. по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10

E R Sopiya

Eli Lilly and Company

канд. мед. наук, ст. мед. конс. по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10

E A Sholokhova

Eli Lilly and Company

Email: Sholokhova_evgeniya@lilly.com
ст. мед. советник по онкологии 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10

A B Gurochkin

Eli Lilly and Company

канд. мед. наук, мед. дир. 123112, Russian Federation, Moscow, Presnenskaia nab., d. 10

References

  1. Ervik M, Lam F, Ferlay J et al. Cancer Today. Lyon, France: International Agency for Research on Cancer. Cancer Today 2016. http://gco.iarc.fr/today
  2. Wagner A.D, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24 (18): 2903-9.
  3. Spratlin J.L, Cohen R.B, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28 (5): 780-7.
  4. Tian S, Quan H, Xie C et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102 (7): 1374-80.
  5. Fuchs C.S, Tomasek J, Yong C.J et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383 (9911): 31-9.
  6. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15 (11): 1224-35.
  7. Cyramza [product guide]: Indianapolis, IN: Eli Lilly and Company, 2016. http://www.cyramzahcp.com/img/pdf/CYRAMZA_Product_ Guide.pdf
  8. European Medicines Agency. Cyramza, summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002829/WC5001 80724.pdf
  9. Hamnvik O.P, Choueiri T.K, Turchin A. et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121 (2): 311-9.
  10. Pacheco S, Norero E, Canales C et al. The Rare and Challenging Presentation of Gastric Cancer during Pregnancy: A Report of Three Cases. J Gastric Cancer 2016; 16 (4): 271-6.
  11. Tabernero T, Ohtsu A, Muro K et al. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther 2017; 16 (10): 2215-22.
  12. Fuchs C.S, Tabernero J, l-Batran S.E et al. A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). J Clin Oncol 2016; 33 (4 Suppl.): TPS178.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies